⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128235 | 0.83 | CPA1 (0.44) | — | |
| SCHEMBL264872 | 0.76 | — | — | |
| SCHEMBL11155338 | 0.74 | — | — | |
| SCHEMBL18463625 | 0.74 | CPA1 (0.54) | — | |
| SCHEMBL27994583 | 0.74 | — | — | |
| SCHEMBL4754546 | 0.73 | — | — | |
| SCHEMBL7220403 | 0.72 | — | — | |
| SCHEMBL66582 | 0.72 | — | — | |
| SCHEMBL17318330 | 0.72 | — | — | |
| SCHEMBL11313334 | 0.72 | CPA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524392-B | As for treating the azetidine of the MEK inhibitor of proliferative disease | 埃克塞利希斯股份有限公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |